1. Introduction to Sitagliptin

Sitagliptin is a DPP-4 (dipeptidyl peptidase-4) inhibitor, marketed under the brand name Januvia® (and as Janumet® in combination with metformin). It is a cornerstone therapy in the management of type 2 diabetes mellitus (T2DM). As a prescription-only medication, it requires careful consideration by pharmacists to ensure safe and effective use.

2. Mechanism of Action

Sitagliptin enhances endogenous glucagon-like peptide-1 (GLP-1) activity by inhibiting DPP-4, an enzyme responsible for the rapid degradation of incretin hormones. GLP-1 stimulates glucose-dependent insulin secretion from pancreatic β-cells and suppresses glucagon release, thereby improving glycemic control without causing significant hypoglycemia when used as monotherapy.

• Evidence Base: Clinical trials (e.g., TECOS, SAVOR-TIMI 52) demonstrate that DPP-4 inhibitors like sitagliptin have a neutral effect on body weight and a low risk of hypoglycemia compared to sulfonylureas or insulin.

3. Indications

• Primary Use: Adjunctive therapy in adults with T2DM to improve glycemic control when used with diet and exercise.
• Not indicated for:
  • Type 1 diabetes mellitus
  • Gestational diabetes
  • Diabetic ketoacidosis (DKA)

4. Dosage and Administration

• Standard Dose: 100 mg once daily, taken orally with or without food.
• Maximum Dose: 100 mg/day (no dose escalation is permitted).
• Timing: Consistent daily administration is critical for maintaining steady plasma levels and maximizing efficacy.

Special Populations:

• Renal Impairment: Sitagliptin is primarily renally excreted; dose adjustment is required for patients with moderate-to-severe renal impairment (eGFR <30 mL/min/1.73m²). The manufacturer recommends avoiding use in such cases.
• Elderly Patients: No specific dose adjustment is needed, but caution is advised due to potential comorbidities and polypharmacy.

5. Pharmacokinetics

• Absorption: Rapid and complete oral absorption; peak plasma concentration occurs within 1–2 hours.
• Metabolism: Minimal hepatic metabolism (CYP3A4/2C9 involvement is negligible).
• Excretion: Primarily via urine (≈60% unchanged), necessitating caution in patients with renal dysfunction.

6. Adverse Effects and Monitoring

Common Side Effects:

• Headache, nasopharyngeal congestion, upper respiratory tract infection, nausea, diarrhea
• These are generally mild and transient.

Serious Adverse Reactions (Require Immediate Discontinuation):

• Hypersensitivity reactions: Rash, pruritus, angioedema, anaphylaxis
• Pancreatitis: Symptoms include severe abdominal pain radiating to the back, nausea/vomiting; elevated lipase/amylase may be present.
• Hepatotoxicity: Elevated transaminases, jaundice (monitor liver enzymes periodically).
• Joint Pain: Rare but reported in some patients.
• Heart Failure: Although DPP-4 inhibitors are generally neutral or beneficial in heart failure, caution is advised in patients with a history of decompensated heart failure.

Pharmacist Role: Educate patients to report persistent or severe symptoms promptly and advise follow-up with their prescriber.

7. Drug Interactions

• Antidiabetic Agents: Concurrent use with insulin, sulfonylureas (e.g., glimepiride), or other oral hypoglycemics may increase hypoglycemia risk.
• Digoxin: Sitagliptin may reduce digoxin absorption; monitor serum levels if co-administered.
• Warfarin: No significant interaction reported, but caution is advised due to potential additive effects on bleeding risk in rare cases.

Clinical Tip: Use tools like Lexicomp or Micromedex to verify interactions before dispensing combination therapies.

8. Special Considerations

Alcohol Use:

• Chronic heavy alcohol consumption may exacerbate hypoglycemia risk, especially when combined with other glucose-lowering agents. Counsel patients accordingly.

Pregnancy and Lactation:

• Contraindicated in pregnancy (Category C) due to limited human data. Risks include potential fetal harm; alternative therapies (e.g., insulin) are preferred.
• Lactation: Excretion into breast milk has not been documented; use with caution or avoid during breastfeeding.

Renal Impairment:

• Avoid in patients with eGFR <30 mL/min/1.73m² due to increased risk of accumulation and toxicity.

Cardiovascular Risk:

• SAVOR-TIMI 52 trial found sitagliptin associated with a slight increase in heart failure hospitalizations compared to placebo. Use caution in patients with established HF or decompensated HF.

9. Storage and Stability

• Store at 20–25°C (68–77°F); excursions up to 15–30°C (59–86°F) are acceptable for short-term storage.
• Protect from moisture and light.

10. Patient Counseling Points

• Take with food if gastrointestinal upset occurs.
• Maintain regular HbA1c testing and monitor for symptoms of hypo/hyperglycemia.
• Report signs of infection, fever, or allergic reactions immediately.
• Avoid alcohol to reduce hypoglycemia risk.

11. Summary for Clinical Practice

Sitagliptin is a well-tolerated, weight-neutral DPP-4 inhibitor with a favorable safety profile when used appropriately. Pharmacists play a pivotal role in:

• Ensuring adherence to dosing guidelines.
• Identifying and mitigating drug interactions.
• Educating patients on adverse effect recognition.
• Advising on renal function assessment and monitoring.

Evidence-Based References:

• ADA 2023 Standards of Care: Recommends DPP-4 inhibitors as a first-line or add-on therapy in T2DM, particularly in patients at risk for hypoglycemia or weight gain.
• FDA Labeling (Januvia®): Contraindications, warnings, and precautions updated as of 2023.

Final Note: Always verify patient-specific factors (e.g., renal function, comorbidities) before dispensing and collaborate with prescribers to optimize therapy.